Multi‐Autoantibody Testing Identifies Expansion of Reactivity to Targeted Antigens Before a Diagnosis of Rheumatoid Arthritis
Open Access
- 1 July 2024
- journal article
- research article
- Published by Wiley in ACR Open Rheumatology
- Vol. 6 (9) , 587-597
Abstract
Objective: Rheumatoid arthritis (RA) has a “pre‐RA” period in which multiple autoantibodies, including antibodies to citrullinated (cit) proteins (ACPA), rheumatoid factor (RF), anti–peptidyl arginine deiminase (anti‐PAD), among others, have been described; however, few studies have tested all autoantibodies in a single pre‐RA cohort. This study aims to evaluate the prevalence of multiple autoantibodies in pre‐RA and potentially identify an autoantibody profile in pre‐RA that indicates imminent onset of clinical RA.Methods: We evaluated 148 individuals with two pre‐ and one post‐RA diagnosis samples available from the Department of Defense Serum Repository and matched controls. Samples were tested for immuglobulin (Ig) G anti–cyclic cit peptide‐3 (anti‐CCP3), five ACPA fine specificities, five anti‐PAD isoforms, as well as RF IgA and RF IgM using commercial platforms; cutoffs were determined using levels present in <1% of controls.Results: Positivity of anti‐CCP3, RF IgA and RF IgM, anti‐PAD1, anti–cit‐vimentin 2, anti–cit‐fibrinogen, and anti–cit‐histone 1 increased over time in pre‐RA, although anti‐PAD and ACPA fine specificities were predominately present within anti‐CCP3–positive individuals. Within anti‐CCP3–positive samples from the pre‐RA period, positivity for RFs as well as anti‐PAD and ACPA fine specificities classified samples as being closer to the time of RA diagnosis.Conclusion: Multiple autoantibodies are present in pre‐RA and increase in positivity as the time of RA diagnosis approaches. These results confirm previous findings predicting imminent RA and provide a pathway using commercial‐grade assays to assess the risk for and timing of development of clinical RA.Keywords
Funding Information
- Congressionally Directed Medical Research Programs (PR191079)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30 AR079369, T32 AR007534)
This publication has 39 references indexed in Scilit:
- Combinations of Anticyclic Citrullinated Protein Antibody, Rheumatoid Factor, and Serum Calprotectin Positivity Are Associated With the Diagnosis of Rheumatoid Arthritis Within 3 YearsACR Open Rheumatology, 2021
- Third‐Generation Anti–Cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Individuals at Risk of Rheumatoid ArthritisArthritis & Rheumatology, 2020
- Timing of Elevations of Autoantibody Isotypes Prior to Diagnosis of Rheumatoid ArthritisArthritis & Rheumatology, 2019
- N‐Linked Glycans in the Variable Domain of IgG Anti–Citrullinated Protein Antibodies Predict the Development of Rheumatoid ArthritisArthritis & Rheumatology, 2019
- Triple Positivity for Anti–Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti–Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid ArthritisArthritis & Rheumatology, 2018
- Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritisArthritis & Rheumatism, 2010
- Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritisArthritis & Rheumatism, 2010
- Marked differences in fine specificity and isotype usage of the anti–citrullinated protein antibody in health and diseaseArthritis & Rheumatism, 2008
- Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donorsArthritis & Rheumatism, 2004
- Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritisArthritis & Rheumatism, 2003